HYPERSTEALTH
DEAD

Serial Number

90696222

Owner

GENERATE BIOMEDICINES, INC.

Attorney

Jennifer M. Mikulina

Filing Date

May 7, 2021

Add to watchlist:

No watchlists yet
View on USPTO

HYPERSTEALTH Trademark

Serial Number: 90696222

HYPERSTEALTH is a trademark filed by GENERATE BIOMEDICINES, INC. on May 7, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

GENERATE BIOMEDICINES, INC. (17 trademarks)

55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142

Entity Type: 03

Trademark Details

Filing Date

May 7, 2021

Registration Date

Not Registered

Published for Opposition

August 9, 2022

Goods & Services

Providing temporary use of on-line non-downloadable software featuring artificial intelligence, computational methods, and machine learning models for data analysis in the fields of biomedical and genomic research; Providing temporary use of on-line non-downloadable software featuring artificial intelligence, computational methods, and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development; scientific research, namely, research and analysis services for the design and characterization of biologic therapeutic products

Pharmaceutical preparations for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders, but excluding DNA-based gene therapy; therapeutic agents for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders but excluding DNA-based gene therapy; therapeutic pharmaceuticals for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders, but excluding DNA-based gene therapy

Biological and chemical agents for scientific and research use

Downloadable software featuring artificial intelligence, computational methods, and machine learning models for data analysis in the fields of biomedical and genomic research; downloadable software featuring artificial intelligence, computational methods, and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Nov 7, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Nov 7, 2025 ABN6
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 3, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 3, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 3, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 3, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 3, 2025 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 24, 2025 EXRA
SOU EXTENSION 5 GRANTED
Apr 24, 2025 EX5G
SOU EXTENSION 5 FILED
Mar 24, 2025 EXT5
SOU TEAS EXTENSION RECEIVED
Mar 24, 2025 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 3, 2025 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 3, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 3, 2025 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 13, 2024 EXRA
SOU EXTENSION 4 GRANTED
Sep 13, 2024 EX4G
SOU EXTENSION 4 FILED
Sep 13, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Sep 13, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 14, 2024 EXRA
SOU EXTENSION 3 GRANTED
Mar 13, 2024 EX3G
SOU EXTENSION 3 FILED
Mar 13, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 13, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 19, 2023 EXRA
SOU EXTENSION 2 GRANTED
Sep 15, 2023 EX2G
SOU EXTENSION 2 FILED
Sep 15, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Sep 15, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 1, 2023 EXRA
SOU EXTENSION 1 GRANTED
Mar 30, 2023 EX1G
SOU EXTENSION 1 FILED
Mar 30, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 30, 2023 EEXT
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 22, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 22, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 22, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 22, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 22, 2022 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 4, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 9, 2022 NPUB
PUBLISHED FOR OPPOSITION
Aug 9, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 20, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 5, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 5, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 5, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 5, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 5, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 1, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 1, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 1, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 12, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jan 12, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jan 12, 2022 CNRT
ASSIGNED TO EXAMINER
Jan 12, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 9, 2021 NWOS